Tranexamic Acid /ml Inj
Phase 3Small molecule
Tranexamic Acid /ml Inj is one of 28 small molecule programs targeting Delirium. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
167 competitors in Delirium
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskPhase 3
Lidocaine IV
KKasr El Aini Hospital
Phase 3
Physostigmine
AstraZenecaPhase 3
Rozerem
TakedaPreclinical
Tranexamic Acid /ml Inj
BBayside Health
Phase 3
Inapsine
Alnylam PharmaceuticalsPreclinical
Anerem
AAcacia Pharma Ltd
Preclinical
Spravato
WWim Janssens
Preclinical
Raldesy
PPragma
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tranexamic Acid /ml Inj. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBayside Health